Weight-loss drugs may affect cancer risk through immune changes
Summarised from 3 outlets · Updated 27 Sept, 11:48 · Archive
GLP-1 drugs like Ozempic and Wegovy may lower cancer risk by altering immune response.
GLP-1 weight-loss drugs such as Ozempic and Wegovy may play a role in cancer outcomes by altering the body's immune response, though researchers say key clinical trials are needed. The American Association for Cancer Research's 2026 Cancer Progress Report noted that obesity is a major risk factor for many cancers. The Mirror reports that nutritional support should play a critical role once treatment with a GLP-1 medication is initiated.

How it is being reported
- New study warning over deficiencies after taking Wegovy, Liraglutide'Nutritional support needs to play a critical role once treatment with a GLP-1 medication is initiated'The Mirror · 27 Sept, 11:32
- GLP-1 drugs could play surprising role in cancer risk and outcomesThe American Association for Cancer Research's 2026 Cancer Progress Report, released earlier this month, noted that obesity is a major risk factor for many cancers.New York Post · 25 Sept, 19:41
- Popular weight-loss drugs may play surprising role in cancer outcomesGLP-1 drugs like Ozempic and Wegovy may lower cancer risk by altering the body's immune response, but researchers say key clinical trials are needed.Fox News · 25 Sept, 12:00
In this story: Ozempic · Wegovy · Liraglutide · American Association for Cancer Research
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)